Allergan CEO Brent Saunders received $32.8 million as the drugmaker's shares fell, Bloomberg reports.
Here's what you should know.
1. Mr. Saunders was awarded $22.7 million in restricted stock. Approximately 75 percent of it will only vest if the company meets goals related to shareholder returns as well as research and development.
2. Mr. Saunders also received $8.75 million in cash bonuses, boosting his base salary by $1.3 million.
3. In 2017, Allergan's shares decreased in value by 22 percent, while the rest of the S&P 500 Health Care Index increased 20 percent.